Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Tap

Showing results (171-180 of 235) with videos related to

Pageof 24
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2025
Letetresgene Autoleucel in Advanced/Metastatic Myxoid/Round Cell LiposarcomaSandra P D'Angelo, Mihaela Druta, Brian A Van Tine, et al.
Nature Communications|June 17, 2024
Cancer-associated Histone H3 N-terminal arginine mutations disrupt PRC2 activity and impair differentiationBenjamin A Nacev, Yakshi Dabas, Matthew R Paul, et al.
JAMA Oncology|February 15, 2017
Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033Michael C Heinrich, Cathryn Rankin, Charles D Blanke, et al.
Lancet (London, England)|June 14, 2016
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trialWilliam D Tap, Robin L Jones, Brian A Van Tine, et al.
Nature Communications|October 22, 2024
Author Correction: Cancer-associated Histone H3 N-terminal arginine mutations disrupt PRC2 activity and impair differentiationBenjamin A Nacev, Yakshi Dabas, Matthew R Paul, et al.
Cancer|November 12, 2024
A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinibJayesh Desai, Andrew J Wagner, Irene Carrasco Garcia, et al.
Nature Genetics|September 22, 2014
PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumorsWilliam Lee, Sewit Teckie, Thomas Wiesner, et al.
The Lancet. Oncology|July 3, 2020
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trialMichael C Heinrich, Robin L Jones, Margaret von Mehren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 3, 2021
Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III StudyYoon-Koo Kang, Suzanne George, Robin L Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2022
A Phase Ib/II Randomized Study of RO4929097, a Gamma-Secretase or Notch Inhibitor with or without Vismodegib, a Hedgehog Inhibitor, in Advanced SarcomaMrinal M Gounder, Evan Rosenbaum, Nian Wu, et al.
Pageof 24

Showing results (171-180 of 235) with videos related to

Sort By:
Pageof 24
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2025
Letetresgene Autoleucel in Advanced/Metastatic Myxoid/Round Cell LiposarcomaSandra P D'Angelo, Mihaela Druta, Brian A Van Tine, et al.
Nature Communications|June 17, 2024
Cancer-associated Histone H3 N-terminal arginine mutations disrupt PRC2 activity and impair differentiationBenjamin A Nacev, Yakshi Dabas, Matthew R Paul, et al.
JAMA Oncology|February 15, 2017
Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033Michael C Heinrich, Cathryn Rankin, Charles D Blanke, et al.
Lancet (London, England)|June 14, 2016
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trialWilliam D Tap, Robin L Jones, Brian A Van Tine, et al.
Nature Communications|October 22, 2024
Author Correction: Cancer-associated Histone H3 N-terminal arginine mutations disrupt PRC2 activity and impair differentiationBenjamin A Nacev, Yakshi Dabas, Matthew R Paul, et al.
Cancer|November 12, 2024
A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinibJayesh Desai, Andrew J Wagner, Irene Carrasco Garcia, et al.
Nature Genetics|September 22, 2014
PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumorsWilliam Lee, Sewit Teckie, Thomas Wiesner, et al.
The Lancet. Oncology|July 3, 2020
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trialMichael C Heinrich, Robin L Jones, Margaret von Mehren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 3, 2021
Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III StudyYoon-Koo Kang, Suzanne George, Robin L Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2022
A Phase Ib/II Randomized Study of RO4929097, a Gamma-Secretase or Notch Inhibitor with or without Vismodegib, a Hedgehog Inhibitor, in Advanced SarcomaMrinal M Gounder, Evan Rosenbaum, Nian Wu, et al.
Pageof 24